INTRODUCTION
============

Testicular germ cell cancer (TGCC) represents the most-frequently diagnosed cancer in young men between 20 and 40 years of age. The rates vary considerably according to region and ethnicity, which suggests that both environmental and genetic factors contribute to TGCC. In Europe, a three- to fourfold increased incidence has been noted during the past 30--40 years, which suggests that an increased exposure to persistent environmental pollutants may play an important role.

Common persistent environmental pollutants include dioxins and polycyclic aromatic hydrocarbons, which exert their toxic and carcinogenic effects through the ligand-activated transcription factor aryl hydrocarbon receptor (AHR). In complex with its binding partner AHR nuclear translocator (ARNT), it mediates cellular responses to xenobiotic compounds. The AHR/ARNT heterodimer stimulates the expression of AHR repressor (AHRR), which provides a negative feedback regulation by competing with ARNT for binding to AHR ([@B22]).

Testicular germ cell cancer derives from carcinoma *in situ* (CIS) cells, also known as intratubular germ-cell neoplasia unclassified ([@B33]; [@B26]), that are believed to arise from primordial germ cells that are blocked in differentiation. The initial malignant transformation of germ cells is thought to be caused by hormonal disturbances in the microenvironment of differentiating germ cells ([@B32]; [@B31]; [@B27]). An association of TGCC with maternal estrogen and androgen levels in early pregnancy has recently been reported, supporting this hypothesis ([@B12]). In addition to altering transcription of steroidogenic genes, such as cytochrome P450 enzymes, the AHR signaling pathway has been shown to interface with estrogen and androgen receptor signaling ([@B14]; [@B15]; [@B29]; [@B3]; [@B2]; [@B18]). Additionally, AHR plays a significant role in tumor promotion and progression by deregulation of cell--cell contact and inhibition of apoptosis ([@B24]; [@B9]; [@B6]; [@B7]; [@B8]).

The risk of environment-related carcinogenesis depends not only on the magnitude of the exposure, but also on individual susceptibility to the pollutant. Therefore, we aimed to analyze the association between polymorphic variants of genes encoding AHR and AHRR and the risk as well as histological and clinical features of TGCC.

MATERIALS AND METHODS {#s1}
=====================

The cohort consisted of TGCC patients from Sweden and Denmark, two neighboring Scandinavian countries, with populations sharing largely the same genetic background as both descended from a common ancestral population.

SWEDISH TGCC PATIENTS
---------------------

All TGCC patients that were referred to the Department of Oncology, Skåne University Hospital, Lund, the Department of Oncology, Radiumhemmet or Södersjukhuset, Karolinska University Hospital, Stockholm since March 1996 and November 1998 until October 2006, respectively, were asked to participate in a study focusing on reproductive function. In total 460 patients were eligible for the study, of which 75 declined to participate and 45 were excluded due to linguistic problems, bilateral testicular cancer, physical handicap, or moving to another region. Seven patients were excluded due to compromising mental conditions, 10 were excluded due to contra-lateral testicular cancer diagnosed after inclusion and 3 died of progressive disease before blood samples were obtained. Among the 320 participants in the study on reproductive function, no DNA was available for 39. Additionally, 3 patients were excluded due to extra-gonadal germ cell cancer, leaving the total at 278. All patients gave their informed written consent and the study was approved by the Ethical Boards of Lund University and Karolinska Institute.

DANISH TGCC PATIENTS
--------------------

In the period between 1999 and 2008, DNA was collected from approximately 300 TGCC patients on the occasion of semen banking prior to surgery or fertility assessment after treatment. One hundred samples were random selected for this study; the criterion for selection being sufficient DNA amount. In total, 11 patients were excluded because of mistaken diagnosis (*n* = 6), purely extra-gonadal tumor (*n* = 4), and in one case because the genetic SNP analysis failed. Among the remaining 89 patients, 5 presented with CIS only and were therefore not included in the analysis of distribution of seminomas (SE) versus non-seminomas (NSE). For six patients no information on stage was available.

CONTROL SUBJECTS
----------------

Control subjects were recruited in a study of reproductive function among Swedish military conscripts aged 18--20 years in the period 2000--2001 ([@B28]). As part of the investigation, scrotal palpation and ultrasound was performed in order to exclude testicular tumors or microcalcifications, which are indicative of an increased risk of CIS. Furthermore, they delivered one ejaculate for semen analysis as well as a blood sample for assessment of hormone levels. Among the 305 men that were eligible, 214 men with a Swedish mother were selected as control subjects (**Table [1](#T1){ref-type="table"}**).

###### 

Characteristics of controls and case patients.

                                  Control      TGCC-SE      TGCC-DK
  ------------------------------- ------------ ------------ -----------
  *n*                             214          278          89
  Age (year)                      18 ± 0       31 ± 7       31 ± 8
  **Histology**                                             
  NSE                                          153 (55.0)   34 (38.2)
  SE                                           125 (45.0)   50 (56.2)
  CIS only                                                  5 (5.6)
  **Stage**                                                 
  Localized                                    200 (71.9)   65 (73.0)
  Metastasis                                   78 (28.1)    18 (20.2)
  Unknown                                                   6 (6.7)
  **Family history of TGCC**                                
  Yes                             0 (0)        9 (3.2)      7 (2.3)
  No                              214 (100)    250 (90.3)   77 (88.5)
  Unknown                                      19 (6.5)     5 (9.2)
  **History of cryptorchidism**                             
  Yes                             7 (3.3)      23 (8.3)     13 (14.6)
  No                              207 (96.7)   247 (88.9)   63 (70.8)
  Unknown                                      8 (2.9)      13 (14.6)

GENOTYPING
----------

Genomic DNA was prepared from peripheral leukocytes using QIAamp DNA Maxi Kit (Qiagen, Germany). All samples were normalized to the same DNA concentration and the genotypes were determined using the Sequenom MassArray MALDI-TOF mass spectrometry. Eleven SNPs in the gene encoding aryl hydrocarbon receptor (*AHR*) and 18 SNPs in the gene encoding aryl hydrocarbon receptor repressor (*AHRR*) with a minor allele frequency \>0.05 that were identified as haplotype-tagging SNPs were selected using dbSNP (available at: <http://www.ncbi.nlm.nih.gov/SNP>) and SNP assays were designed using MassArray Assay Design ver. 2 software (Sequenom Inc., USA). Primers were obtained from Metabion GmbH (Germany) and all reactions were run under the same conditions, except for the primer annealing temperature of the primary PCR. PCR reactions were performed in a total volume of 6 μL containing 2.5 ng template DNA, 1.25× *Taq* PCR buffer (Hotstar, Qiagen), 0.15 U *Taq* polymerase (Hotstar, Qiagen), 3.5 nM MgCl~2~, 0.5 mM dNTP, and 100 nM of each primer. Amplifications were performed using GeneAmp 9700 machines with dual-384 heads as follows: 95°C for 15 min, 45 cycles at 95°C for 20 s, 56°C, 60°C, or 64°C for 30 s, 72°C for 60 s, and finally 72°C for 3 min. Dephosphorylation of unincorporated dNTP was achieved using shrimp alkaline phosphatase. Concentrations of individual homogenous MassEXTEND (hME) primers were adjusted to even out peak heights in the mass spectrum. The extension reactions were carried out by mixing the adjusted primer mix (containing approximately 1 μM of each primer) with hME mix containing buffer and 50 μM of each d/ddNTP mix and 1.25 U of Thermo Sequenase (Amersham Biosciences, Uppsala, Sweden). PCR amplification of hME reactions was performed as follows: 94°C for 2 min and 99 cycles at 94°C for 5 s, 52°C for 5 s, and 72°C for 5 s. The samples were then manually desalted by using 6 mg of Clean Resin and a dimple plate and subsequently transferred to a 384-well SpectroCHIP using a nanodispenser. Randomly selected samples of each genotype were directly sequenced in order to validate the SNP assays.

STATISTICAL ANALYSIS
--------------------

Single-nucleotide polymorphisms data was processed and analyzed using the web-based SNPator data analysis suite ([@B23]). Agreement with Hardy--Weinberg equilibrium was tested using a χ^2^ goodness-of-fit test. TGCC patients were divided in two groups depending on whether they were diagnosed with SE or NSE. Logistic regression association was used to calculate the odds ratio (OR) and 95% confident interval for developing TGCC, for developing either SE or NSE, and for developing disseminated disease \[defined by stages II, III, and IV according to the Royal Marsden Hospital staging classification ([@B13]), with stage I disease defined as tumor confined to the testis, with no evidence of metastases\]. In the latter analysis histological subtype was included as a covariant in the logistic regression. Associations were considered statistically significant at *p* \< 0.05. Assuming a co-dominant additive model, we tested a linear trend of increasing effect in the different genotypes using linear-by-linear association χ^2^ statistics (SPSS ver. 21). Linkage disequilibrium (LD; i.e., non-random association of alleles) was assessed for each gene. The LD between identified SNPs was determined by pairwise comparisons of correlation coefficient between SNPs (*r*) and the likelihood that recombination has occurred between SNPs (*D*′). Since we expected that the selected SNPs have a small contribution to TGCC and we regard our study to be exploratory rather than confirmatory, we have chosen to avoid correction for multiple testing. This may increase the risk of type 1 errors, but it prevents type 2 errors.

RESULTS
=======

No significant deviations from Hardy--Weinberg equilibrium were detected for the SNPs included in the analysis.

We did not find a statistically significant association between the studied polymorphisms and the risk of TGCC.

For four SNPs in *AHRR* a significant allele association with the occurrence of disseminated disease was observed (**Table [2](#T2){ref-type="table"}**). Patients with metastatic disease had significantly lower frequencies of the minor rs2466287 G, rs2672725 G, rs6879758 C, and rs6896163 G alleles compared to patients with localized disease (5 vs 10%, 6 vs 11%, 2 vs 5%, and 2 vs 6%, respectively), which were associated with 57, 51, 73, and 66%, reduced per allele OR for developing metastatic TGCC, respectively. Heterozygous carriers of *AHRR* variants rs6879758 and rs6896163 had a 74 and 67% reduced risk of developing metastatic TGCC, respectively. Due to very low frequencies, or even absence, of homozygous carriers of the *AHRR* variants the OR could not be calculated for these groups of patients. However, trend analyses demonstrated significant associations for all four *AHRR* variants.

###### 

Allele and genotype distributions with associated OR and trend analysis in TGCC patients stratified according to the occurrence of metastasis.

  SNP (gene)           Allele and genotype   Combined   Sweden     Denmark                                                                                                        
  -------------------- --------------------- ---------- ---------- --------- -------------------- ---------- ---------- ------- -------------------- ---------- --------- ------- ---------------------
  rs2466287 *(AHRR)*   C                     472 (90)   181 (95)             Referent             356 (90)   147 (95)           Referent             116 (89)   34 (94)           Referent
                       G                     54 (10)    9 (5)      0.021     0.43 (0.21--0.90)    40 (10)    7 (5)      0.036   0.42 (0.19--0.97)    14 (11)    2 (6)     0.348   0.49 (0.11--2.27)
                       CC                    213 (81)   86 (91)              Referent             161 (81)   70 (91)            Referent             52 (80)    16 (89)           Referent
                       CG                    46 (17)    9 (9)      0.061     0.49 (0.23--1.03)    34 (17)    7 (9)      0.089   0.47 (0.20--1.12)    12 (18)    2 (11)    0.026   0.098 (0.013--0.75)
                       GG                    4 (2)      0 (0)      --        --                   3 (2)      0 (0)      --      --                   1 (2)      0 (0)     --      --
                       Trend                                       0.024                                                0.041                                             0.359   
  rs2672725 *(AHRR)*   C                     467 (89)   179 (94)             Referent             351 (89)   146 (95)           Referent             116 (89)   33 (92)           Referent
                       G                     59 (11)    11 (6)     0.031     0.49 (0.25--0.94)    45 (11)    8 (5)      0.028   0.43 (0.20--0.93)    14 (11)    3 (8)     0.670   0.75 (0.20--2.78)
                       CC                    209 (79)   84 (88)              Referent             157 (79)   69 (90)            Referent             52 (80)    15 (83)           Referent
                       CG                    49 (19)    11 (12)    0.104     0.56 (0.28--1.13)    37 (19)    8 (10)     0.088   0.49 (0.22--1.11)    12 (18)    3 (17)    0.014   0.078 (0.010--0.60)
                       GG                    5 (2)      0 (0)      --        --                   4 (2)      0 (0)      --      --                   1 (2)      0 (0)     --      --
                       Trend                                       0.035                                                0.033                                             0.674   
  rs6879758 *(AHRR)*   G                     499 (95)   187 (98)             Referent             375 (94)   152 (99)           Referent             124 (95)   35 (97)           Referent
                       C                     29 (5)     3 (2)      0.025     0.27 (0.08--0.92)    23 (6)     2 (1)      0.023   0.21 (0.050--0.92)   6 (5)      1 (3)     0.627   0.59 (0.069--5.00)
                       GG                    235 (89)   92 (97)              Referent             176 (88)   75 (97)            Referent             59 (91)    17 (94)           Referent
                       GC                    29 (11)    3 (3)      0.032     0.26 (0.079--0.89)   23 (12)    2 (3)      0.034   0.20 (0.047--0.89)   6 (9)      1 (6)     0.147   0.32 (0.070--1.49)
                       CC                    0 (0)      0 (0)      --        --                   0 (0)      0 (0)      --      --                   0 (0)      0 (0)     --      --
                       Trend                                       0.022                                                0.020                                             0.622   
  rs6896163 *(AHRR)*   A                     497 (94)   188 (98)             Referent             373(94)    153 (98)           Referent             124 (95)   35 (97)           Referent
                       G                     31 (6)     4 (2)      0.037     0.34 (0.12--0.98)    25 (6)     3 (2)      0.035   0.29 (0.087--0.98)   6 (5)      1 (3)     0.627   0.59 (0.069--5.00)
                       AA                    233 (88)   92 (96)              Referent             174 (87)   75 (96)            Referent             59 (59)    17 (94)           Referent
                       AG                    31 (12)    4 (4)      0.040     0.33 (0.11--0.95)    25 (13)    3 (4)      0.041   0.28 (0.082--0.95)   6 (6)      1 (6)     0.180   0.41 (0.11--1.50)
                       GG                    0 (0)      0 (0)      --        --                   0 (0)      0 (0)      --      --                   0 (0)      0 (0)     --      --
                       Trend                                       0.032                                                0.031                                             0.622   

Polymorphisms in *AHRR* did not show a significant association with risk of TGCC or histological subtype, which was also the case for SNPs in *AHR*. Histological subtype and the occurrence of metastasic disease were not associated with SNPs in *AHR*. LD analysis demonstrated a high correlation between rs2466287 and rs2672725 as well as between rs6879758 and rs6896163 (**Table [3](#T3){ref-type="table"}**).

###### 

Linkage disequilibrium (*D*′) and correlation coefficients (*r*) between SNPs in *AHRR* that associate with metastatic TGCC in the total population.

              rs2466287   rs2672725   rs6879758                   
  ----------- ----------- ----------- ----------- ------- ------- -------
  rs2466287                                                       
  rs2672725   0.978       0.909                                   
  rs6879758   0.239       0.172       0.230       0.155           
  rs6896163   0.195       0.142       0.186       0.132   0.999   0.948

When analyzed in the two populations individually, similar statistically significant ORs for the four SNPs were observed in the Swedish population as compared to the combined population. The associations in the Danish populations showed similar tendencies, although these did not reach statistical significance.

DISCUSSION
==========

In this study we have analyzed associations between SNPs in genes encoding AHR and AHRR and the risk of developing TGCC, histological subtype, and the occurrence of metastasis. Whereas no associations were found with SNPs in *AHR*, four variants in *AHRR* associated significantly with the occurrence of metastatic disease.

Both AHR and its negative regulator AHRR are ligand-activated transcription factors that belong to the family of basic helix-loop-helix Per-Arnt-Sim (bHLH-PAS) proteins. They are ubiquitously expressed in almost all human tissues, with levels particularly high in the testis ([@B5]; [@B35]). 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD) is the most well-characterized exogenous ligand of AHR and it is known for its anti-estrogenic properties such as inhibition of estradiol-induced uterine weight increase and decreased levels of estrogen and progesterone receptors in uterus of rat and mice ([@B30]).

Several epidemiological studies have shown that TCDD promotes cancer, and experiments in AHR-deficient mice have shown that AHR is essential for the tumor-promoting effects of TCDD ([@B1]; [@B21]). Conversely, transgenic mice with a constitutively active AHR spontaneously develop tumors, their weights of testis and ventral prostate are decreased and the epididymal sperm reserve is reduced ([@B4]). Furthermore, AHRR, the negative regulator of AHR signaling, functions as a tumor suppressor in multiple human tumors ([@B36]; [@B19]). Several studies have shown that the AHR activation also interferes with reproductive health. An increased incidence of TGCC has been observed in workers exposed to TCDD ([@B16]) and dioxins have been reported to reduce sperm number, and to decrease accessory sex gland weight and anogenital distance in rats ([@B20]; [@B11]; [@B34]; [@B10]; [@B25]).

While SNPs in either AHR or AHRR did not associate with the risk of TGCC, it is interesting that an association was observed between AHRR and dissemination of TGCC, since AHR signaling is indeed known to contribute to the control of cell adhesion and migration ([@B6]; [@B8]). A potential role of AHR signaling in dissemination of TGCC is further supported by [@B17] who reported that AHR agonists decreased anchorage-independent pancreatic cancer cell growth.

Since testicular cancer rarely occurs before the onset of puberty, the malignant transformation of CIS cells may be associated with activation of the hypothalamic--pituitary--gonadal axis. An interaction between AHR signaling and steroid or gonadotropic hormones could therefore be an alternative mechanism underlying the association between AHRR polymorphisms and metastatic TGCC.

A strength of our study is the access to two independent TGCC populations. Although not all findings reached statistical significance in the Danish cohort when the countries were analyzed separately, most probably due to the limited number of cases in this group, the same trends with similar relative risks were found, which strengthens the relevance of our findings. We cannot exclude that a small fraction of the TGCC patients in our cohort were from non-Caucasian background. However, none of the allele frequencies of the analysed SNPs deviated from Hardy-Weinberg equilibrium, which indicates that either the non-Caucasian allele frequencies did not differ from those in the Caucasian population, or that non-Caucasians did not significantly contribute to the total cohort. The SNPs identified in this study are intronic polymorphisms, thus excluding structural changes in the proteins that these genes encode. Yet, polymorphisms in non-coding regions can still play an important role in the regulation of gene expression, e.g., by affecting mRNA stability, regulation by intronic micro RNAs, or potential splice sites. The identified SNPs could also be in LD with other genetic polymorphisms that are causally related to TGCC.

In summary, we have identified polymorphic variants in the gene encoding AHRR that associated with risk of disseminated TGCC. This supports our hypothesis that the AHR signaling pathway may affect the progression of TGCC, possibly by interfering with reproductive hormone actions.
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